O51-1 - Serum Uric Acid Increase through the Treatment of Acute Decompensated Heart Failure Might Predict Adverse Outcome

Abstract

Background: Elevated serum uric acid (UA) is associated with an increased risk of adverse outcome in patients with chronic heart failure (CHF), however it remains still unknown whether the change of serum UA level predicts adverse events in CHF patients. Objective: The purpose of this study was to determine if in-hospital UA increase, after stabilization of acute decompensated HF (ADHF) predicts adverse events. Methods and Results: We retrospectively analyzed consecutive 492 patients who were hospitalized for ADHF, and their attending physicians evaluated UA levels at the hospitalization and before discharge. We followed them up until they had composite endpoint of re-hospitalization for ADHF or death for the first time after discharge. UA levels both at admission and at discharge were available in 292 patients. UA values increased (I group) in 92 patients and it decreased in the remaining 200 patients (D group). At hospitalization I group were significantly older (77.6 ± 11.0 vs. 73.0 ± 12.7 years old, P < .0001) and their hemoglobin and serum UA level were significantly lower than D group (hemoglobin, 11.7 ± 1.9 vs. 12.4 ± 2.4 g/dl, P = .0008; UA, 6.0 ± 1.6 vs. 7.7 ± 2.1 mg/dl, P < .0001 respectively) . UA increase was associated with higher incidence of endpoint (38.0% vs. 30.5%, P = .0487, log-rank test). Conclusion: In CHF patients, increase of UA through the treatment of ADHF might predict adverse outcome.